# Cheap-to-Truth by Machine Over Human

Canonical: https://truth.machineoverhuman.com/

Cheap-to-Truth is an independent research and diligence service for drug-development opportunities.

Primary paid offer:
- Cheap-to-Truth Diligence Sprint
- One-time fee: USD 4,950
- Live checkout: https://book.stripe.com/4gM6oJfj18NbgMi6jf0RG1z

The work is designed to answer one question: what is the cheapest credible path to a decision-relevant truth about an asset and indication?

The public Mega OBZ demo scores opportunity dimensions including addressable population, unmet need, human safety, efficacy signal, biological plausibility, rights clarity, patent runway, endpoint objectivity, readout speed, sample size, recruitment ease, participant burden, site specialization, lab burden, cold chain, route, monitoring burden, regulatory usability, geography options, cost, probability of a decisive signal, and commercial upside.

Hard gates are not averaged away. Safety, rights, scientific validity, and regulator usability can stop an opportunity regardless of headline economics.

Escalation paths:
1. Flat-fee diligence sprint.
2. Separately negotiated success-based asset sourcing.
3. Separately negotiated virtual-biotech operating model around selected assets.

This is research and strategic diligence. It is not medical care, legal advice, investment advice, a securities offering, or a guarantee of clinical or regulatory success.

Related:
- Machine Over Human: https://machineoverhuman.com/
- Universal Document: https://universaldocument.org/